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doi:10.1016/j.jtcvs.2003.11.048278 The Journal of Thoracic and CardioObjective: The study’s objective was to examine factors associated with persistent
or recurrent congestive heart failure after mitral valve replacement.
Methods: Patients who underwent mitral valve replacement with contemporary
prostheses (N  708) were followed with annual clinical assessment and echocar-
diography. Cox proportional hazard models were developed to evaluate the impact
of demographic, comorbid, and valve-related variables on the occurrence of con-
gestive heart failure after mitral valve replacement, defined as the composite
outcome of New York Heart Association class III or IV symptoms or death caused
by congestive heart failure postoperatively. Factors associated with all-cause mor-
tality were also examined. Models were bootstrapped 1000 times.
Results: The total follow-up was 3376 patient-years (mean 4.8  3.7 years, range
60 days to 17.1 years). Freedom from New York Heart Association III or IV
symptoms or death caused by congestive heart failure was 96.1% 0.8%, 82.7%
1.7%, 66.4%  3.0%, and 38.8%  6.9% at 1, 5, 10, and 15 years, respectively.
Preoperative New York Heart Association class, left ventricular grade, atrial fibril-
lation, coronary artery disease, smoking, persistent tricuspid regurgitation, and redo
status predicted congestive heart failure postoperatively (all P  .05). Patients who
underwent mitral valve replacement for pure mitral stenosis had less congestive
heart failure events after surgery than those with regurgitation or mixed disease.
Prosthesis size and elevated transprosthesis gradients were not predictive of freedom
from congestive heart failure after mitral valve replacement. Atrial fibrillation,
persistent tricuspid regurgitation, and surgical referral for mitral valve replacement
at an advanced functional stage were also risk factors for all-cause mortality.
Conclusions: This study identifies the incidence of and risk factors for congestive
heart failure and death late after mitral valve replacement. Although prosthesis size
has no effect, other potentially modifiable factors such as atrial fibrillation, persis-
tent tricuspid regurgitation, and late surgical referral have a negative impact on
freedom from congestive heart failure and overall survival after mitral valve
replacement.
Although mitral valve replacement (MVR) is no longer the surgicaltreatment of choice for mitral valve disease, it remains commonlyused for some indications, such as redo mitral surgery and thetreatment of advanced stenotic or mixed lesions, endocarditis, orischemic mitral insufficiency. As for other valve operations, animportant goal of MVR is to prevent or cure symptoms of con-
gestive heart failure (CHF) and decrease the likelihood of CHF-related death,1 but
few studies have systematically examined the impact of patient- and prosthesis-
related characteristics on this outcome. This study addresses this question with a
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another article that focused on the same issue after aortic
valve replacement (AVR).2 Furthermore, in light of our
AVR data, this study also ascertains whether prosthesis size
has an impact on specific functional CHF end points after
MVR. Previous studies on mitral prosthesis size may have
been limited (similar to other studies that examined this
issue in patients after AVR) by the nonspecificity of all-
cause mortality as a clinical indicator of cardiac perfor-
mance after valve replacement.
Methods
Study Population
The general methodology of this study has been described.2
Briefly, adult patients (aged 18 years) who underwent MVR
between 1976 and 2001 at our institution were followed annually
in a dedicated valve clinic with clinical and laboratory examina-
tions. The preoperative characteristics of the cohort are presented
in Table 1.
Because of the potential impact of the prosthesis on the out-
come of interest, patients who received valves that have since been
withdrawn from the North American market were excluded from
the analyses. Patients who underwent operation after 1990 had
preservation of the posterior leaflet and chordae whenever feasible.
The study cohort included 708 adult patients who underwent
replacement of the mitral valve with prostheses that are still
TABLE 1. Prevalence and mean values of preoperative
variables
Mechanical
(N  493)
Bioprosthetic
(N  215) P
Female gender 62.1% 58.8% .41
Age (y) 59.1 11.2 64.6 13.2 .001
Body surface area (m2) 1.85 0.22 1.81 0.21 .024
NYHA class .17
I 11.7% 13.5%
II 24.4% 19.7%
III 43.9% 39.9%
IV 20.1% 26.9%
Left ventricular grade .54
1 50.8% 51.7%
2 30.6% 29.3%
3 12.7% 17.2%
4 6.0% 1.7%
LVEDP (mm Hg) 16.1 5.4 16.4 11.3 .63
Coronary artery disease 29.4% 32.4% .42
Chronic atrial fibrillation 23.9% 25.0% .75
Primary operative indication .29
Stenosis 21.7% 18.1%
Insufficiency 29.6% 33.3%
Mixed disease 48.6% 48.7%
Previous mitral replacement 18.3% 5.1% .001
Values are reported as mean  SD or percentages.
LVEDP, Left ventricular end-diastolic pressure; NYHA, New York Heart
Association.commercially available today (Table 2) and who survived the
The Journal of Thoraciperioperative period. The total follow-up was 3376 patient-years,
with a mean duration of 4.8  3.7 years (range 60 days-19.9
years). Seventy-seven percent of patients had an average of 3.6
postoperative transthoracic echocardiograms performed at our in-
stitution on an annual basis.
Definition of Heart Failure
Heart failure after valve replacement was defined as (1) New York
Heart Association (NYHA) functional class III or IV for more than
4 consecutive weeks or (2) death in which the primary or main
contributing diagnosis was CHF. The clinical impression was
corroborated with physical examination, chest radiograph, electro-
cardiogram, and echocardiography findings. Cases of primary non-
structural dysfunction resulting from severe paravalvular leaks,
valve thrombosis, or endocarditis were excluded as heart failure
events for the purpose of this study.
Statistical Analyses
Data were imported and analyzed in Intercooled Stata 8 (Stata,
College Station, Tex). Patients were censored at the time of their
last follow-up visit if they had not experienced at least 1 episode
of NYHA functional class III or IV for 4 weeks or more, or had
died from a CHF-related event. Deaths from an unknown cause
were not considered to result from CHF. Crude, stratified, and
risk-adjusted survival, heart failure event rates, and failure rates
are reported as mean  SE or as mean (95% confidence interval
[CI] lower bound, 95% CI upper bound).
Cox proportional hazards models were developed by incorpo-
rating variables that had a P value of .10 or less on univariate
analysis and by forcing into each model patient- and prosthesis-
related variables (eg, age, gender, comorbidities, atrial fibrillation,
and valve type) that constituted potential confounders regardless of
their univariate P value. Variables used in the models are presented
in Tables 3 and 4. To account for positive or negative confounding,
no automated model selection procedure was used, and reported
variables, unless collinear with a Spearman’s rank correlation
coefficient of 0.30 or greater and a P value less than .01, were used
simultaneously. Each model was evaluated with a score test and
rejected if the P value was .05 or greater. Final models were
subjected to 1000 bootstrap replications, and bias-corrected esti-
TABLE 2. Implanted mitral prostheses and manufacturer
valve size
Number implanted
(median size; min-max)
Mechanical
Medtronic Hall 215 (29; 23-33)
St Jude Medical 193 (29; 25-33)
Carbomedics 85 (31; 27-33)
Bioprosthetic
Medtronic Hancock I 100 (29; 23-35)
Medtronic Hancock II 95 (29; 25-33)
Edwards Perimount 20 (29; 27-33)mates of 95% CIs were tabulated for significant covariates.
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Cumulative Incidence of Heart Failure Events After
MVR
The freedom from the composite outcome of NYHA func-
tional class III or IV symptoms or CHF-related death in
patients who survived and were followed in a clinic 2
TABLE 3. Predictors of New York Heart Association class
Ha
Significant independent predictors:
Atrial fibrillation
Preoperative NYHA class†
Preoperative left ventricular grade†
Coronary artery disease
Smoking
Redo mitral valve replacement
Tricuspid insufficiency
Pure mitral stenosis
History of previous stroke
Nonsignificant variables included in the model:
Age at surgery (per year increase)
Male gender
Preoperative diastolic pulmonary artery pressure
(per mm Hg)†
Body surface area
Diabetes mellitus
Bioprosthetic (vs mechanical) valve
Bileaflet (vs tilting disk) mechanical valve§
Manufacturer valve size (per one size increase)†
Peak transprosthesis gradient (per mm)‡
Mean transprosthesis gradient (per mm)‡
Peak transprosthesis gradient 90th percentile‡
Mean transprosthesis gradient 90th percentile‡
CI, Confidence interval; NYHA, New York Heart Association.
*Derived from 1000 bootstrap model simulations (reported for significant
†‡Collinear variables that were successively but not simultaneously inclu
§Within subset of mechanical valves.
TABLE 4. Predictors of all-cause death
Haza
Significant independent predictors:
Age at surgery (per year)
Atrial fibrillation
Preoperative NYHA class†
Preoperative left ventricular grade†
Coronary artery disease
Number of pack-years smoked (per pack-year)
Tricuspid insufficiency
CI, Confidence interval; NYHA, New York Heart Association.
Nonsignificant variables also included in the model were male gender, pre
stenosis, redo mitral valve replacement, bioprosthetic (vs mechanical) va
peak‡ and mean‡ transprosthesis gradient 90th percentile.
*Derived from 1000 bootstrap model simulations.
†‡Collinear variables that were successively but not simultaneously inclumonths or more after MVR was 96.1%  0.8%, 82.7% 
280 The Journal of Thoracic and Cardiovascular Surgery ● Augu1.7%, 66.4% 3.0%, and 38.8% 6.9% at 1, 5, 10, and 15
years, respectively. Figure 1 shows the freedom from
NYHA class III or IV symptoms not leading to CHF-related
death (Figure 1, A), the freedom from CHF-related death
(Figure 1, B), and the freedom from all-cause death (Figure
1, C) in patients with mechanical and bioprosthetic mitral
r IV symptoms or CHF-related death
atio 95% CI P
Bias-corrected
95% CI*
1.37-2.82 .001 1.26-2.75
1.14-1.77 .002 1.13-1.77
1.02-1.94 .038 1.02-1.96
1.06-2.35 .025 1.03-2.38
1.14-3.82 .017 1.06-3.53
1.30-3.07 .002 1.18-3.11
1.11-5.43 .027 0.29-105
0.33-0.99 .049 0.30-0.96
1.24-7.92 .016 1.23-5.87
0.99-1.03 .15 –
0.68-1.55 .89 –
0.98-1.03 .49 –
0.41-2.94 .85 –
0.78-3.68 .18 –
0.69-1.51 .91 –
0.81-2.01 .29 –
0.86-1.03 .18 –
0.96-1.06 .75 –
0.94-1.16 .45 –
0.30-1.80 .50 –
0.60-2.61 .55 –
tors only).
the model.
tio 95% CI P
Bias-corrected
95% CI*
1.01-1.06 .001 1.01-1.06
1.10-4.81 .027 1.06-4.57
1.00-1.63 .048 1.00-1.63
1.03-2.09 .033 1.04-2.02
1.16-2.81 .009 1.12-2.74
1.00-1.04 .039 1.00-1.04
1.30-3.63 .003 0.10-106
ative diastolic pulmonary artery pressure,† body surface area, pure mitral
anufacturer valve size, peak‡ and mean‡ transprosthesis gradients, and
the model.III o
zard r
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Patient-related factors. Table 3 displays the risk factors
for heart failure late after MVR. Significant independent
predictors included atrial fibrillation (hazard ratio [HR]:
2.0), preoperative functional class (HR: 1.4 per class in-
crease), left ventricular grade (HR: 1.4 per unit increase),
coronary artery disease at the time of surgery (HR: 1.6),
smoking (HR: 2.1), redo MVR (HR: 2.0), moderate-to-
severe tricuspid insufficiency at follow-up echocardiogra-
phy (HR: 2.5), and a history of stroke preoperatively (HR:
3.1). Patients who underwent MVR for pure mitral stenosis
Figure 1. Cumulative incidence of heart failure events
of the freedom from NYHA class III or IV symptoms (A)
patients with mitral mechanical and bioprosthetic valhad a lower cumulative incidence of heart failure events
The Journal of Thoraciafter surgery (HR: 0.6) than those with mitral insuffi-
ciency or mixed disease, independent of confounding
factors.
Prosthesis-related factors. In contrast with patients with
aortic prostheses,2 prosthesis size did not significantly pre-
dict freedom from heart failure after MVR, regardless of
whether body surface area was accounted for in the model.
The median transprosthesis peak and mean gradient for
patients with a mitral prosthesis were 11 mm Hg and 4 mm
Hg, respectively, and the 90th percentile values for peak and
mean aortic gradients were 19 mm Hg and 7 mm Hg,
death after MVR. Unadjusted Kaplan-Meier estimates
rt failure-related death (B), and all-cause death (C) inand
, hearespectively. Peak and mean transprosthesis gradients had
c and Cardiovascular Surgery ● Volume 128, Number 2 281
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MVR either as a linear relationship or as a dichotomous
predictor defined by a gradient at or above the 90th percen-
tile value of the cohort.
Risk Factors for All-Cause Death
Table 4 displays the risk factors for all-cause death late after
MVR in the study cohort. Significant independent predic-
tors were age, atrial fibrillation, preoperative functional
class, left ventricular grade, coronary artery disease, number
of pack-years smoked, and persistent tricuspid insufficiency
at follow-up. Again, no significant effect of prosthesis size
on crude survival was detected.
Discussion
In this study we identified risk factors for persistent or
recurrent CHF after MVR from a cohort of patients pro-
spectively followed after surgery. Risk factors for the com-
posite outcome of CHF symptoms or CHF-related death
after MVR included chronic atrial fibrillation, advanced
preoperative NYHA class, advanced LV grade, smoking,
tricuspid insufficiency, and preoperative history of stroke.
MVR for pure mitral stenosis was associated with signifi-
cantly less CHF events during follow-up than if MVR had
been performed for mitral regurgitation or mixed disease.
These data have practical relevance in light of some of
the current controversies related to the operative manage-
ment of patients with mitral valve disease. First, patients
with atrial fibrillation have an increased risk of persistent or
recurrent CHF after MVR, raising the question of whether
the use of a concomitant maze procedure might modify this
risk. Previous data have demonstrated that all-cause mor-
tality after mitral valve surgery is lower for patients in sinus
rhythm than for those in atrial fibrillation3 and that, as
expected, freedom from atrial fibrillation after MVR is
higher in patients who concomitantly undergo a maze pro-
cedure.4,5 Our data support the premise that the maze pro-
cedure may be beneficial with respect to CHF outcomes and
all-cause mortality after MVR, and may provide the basis
for a randomized, controlled trial that would examine the
impact of this procedure not only on electrophysiologic,
anticoagulation, and stroke outcomes but also on CHF end
points and functional capacity after MVR and mitral valve
repair.
Another finding of relevance in this study is that persis-
tent tricuspid insufficiency at follow-up was independently
associated with an increased risk of CHF and all-cause
death after MVR, regardless of the severity of symptoms
preoperatively. Although this significant finding was not
robust on bootstrap resampling simulations because of the
relatively small number of linked events, it nevertheless
suggests that the commonly held view stipulating that the
performance of tricuspid valve repair in patients after MVR
282 The Journal of Thoracic and Cardiovascular Surgery ● Auguis dictated by the presence of congestive symptoms may be
unfounded, and that an aggressive approach toward repair of
tricuspid insufficiency in patients after MVR might posi-
tively impact on freedom from CHF late postoperatively. In
this regard, other investigators have also suggested that even
asymptomatic, functional tricuspid insufficiency may war-
rant tricuspid valve repair, because tricuspid insufficiency
may not improve and even worsen with time, especially in
the presence of atrial fibrillation.6
Other aspects of patient management were also identified
as potential CHF risk modifiers in this study. For example,
it is possible that newer trends in the management of pa-
tients with mitral valve disease, such as the referral of
patients for valve surgery before symptom development,
may have an independent positive impact on the freedom
from CHF after MVR.
An important negative finding of this study was that
mitral prosthesis size, within the usual range used for MVR
in adults, did not correlate with functional outcome, free-
dom from CHF death, or overall survival after MVR. These
findings are in contrast with recent work from our group that
examined similar outcomes after AVR and that showed
aortic prosthesis size had a significant independent effect on
freedom from CHF.2 Yazdanbakhsh and colleagues7 indi-
cated that a small valve area index is a risk for early
mortality after MVR (with congestive failure being the main
cause of death), but these authors, as those in the present
study, found no impact of mitral prosthesis size on late
mortality after MVR. In this regard, it is plausible that early
outcomes of surgeries such as MVR may be particularly
susceptible to selection bias, which can persist despite rig-
orous multivariate analysis.8
Smoking was another potentially modifiable risk factor
for CHF after MVR that was identified in this study. Al-
though smoking and its associated impairments in func-
tional capacity may have resulted in more pseudo-CHF
symptoms reported from smokers than nonsmokers, a recent
study from our group indicated that smoking is an indepen-
dent risk factor for structural bioprosthesis degeneration,
which may help explain the impact of smoking on CHF
outcomes observed in the present study.9 Additional evi-
dence pertaining to native valves previously suggested that
cigarette-derived toxins play a biologic role on the structural
integrity of valves through premature calcification.10,11
It is noteworthy that within the number of risk factors
identified, a history of stroke may have been a risk factor for
subsequent stroke12 or a marker of advanced cardiovascular
disease and thus a potential positive confounder of poor
functional status that could not be fully discriminated from
advanced NYHA class symptoms during the follow-up pe-
riod.
Finally, the results of this study also indicate that patients
with pure mitral stenosis who undergo MVR have a signif-
st 2004
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mitral insufficiency or mixed disease and that MVR pro-
vides relatively good functional results in patients for whom
mitral commissurotomy is not feasible. This issue may
warrant further research to determine whether MVR is
better than a suboptimal mitral valve repair in a patient with
advanced mitral stenosis whose valve is poorly amenable to
commissurotomy.
Limitations
This study was not of randomized design. It is possible that
unidentified confounders or selection bias may have influ-
enced results despite the use of specific end points and
bootstrapped methods. Statistical overfitting also may have
enhanced some associations, with one possibility being the
significant relationship of tricuspid insufficiency with CHF
outcomes and death, which could not be verified by boot-
strap resampling because of the relatively small number of
linked events.
Patients lost to follow-up may have had important sub-
sequent outcomes that were not accounted for in the anal-
yses, and the mean follow-up of the study, although extend-
ing to 19.9 years, was only 4.8 years. Inferences therefore
apply mostly to intermediate-term outcomes.
Some entries were incomplete in the database. Although
no data were imputed and the sample size of each analysis
was floated with respect to the number of complete entries,
this approach may have prevented the demonstration of
some associations by increasing type II statistical error,
because some potential predictors were evaluated with sub-
total samples.
Other than for a general consensus to preserve the sub-
valvular mitral apparatus in patients of the cohort who
underwent operation after 1990, specific details pertaining
to the preservation technique used in each patient were not
available from the database. Their impact on CHF outcomes
could therefore not be examined in this study.
Conclusions
This study identified risk factors for the development ofThe Journal of Thoraciadvanced NYHA class and left ventricular grade may be
impacted by earlier referral for valve surgery. Other risk
factors such as postoperative atrial fibrillation and tricuspid
insufficiency warrant further research to define the impact
of concomitant surgical procedures oriented at these condi-
tions on the cumulative incidence of CHF after MVR.
We thank Mary Thomson for her assistance with the organiza-
tion of the valve clinic and management of the database.
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